Stanford University
Showing 51-100 of 289 Results
-
Anyi Rao
Postdoctoral Scholar, Computer Science
Current Research and Scholarly InterestsHuman AI for Creativity, Computer Vision, Graphics, Human-Computer Interaction
-
Ashwin Rao
Adjunct Professor, Institute for Computational and Mathematical Engineering (ICME)
BioMy current research and teaching is in Machine Learning (specifically RL) with applications to Financial Markets and Retail businesses. My academic origins are in Algorithms Theory and Abstract Algebra. More details on my background are here: https://www.linkedin.com/in/ashwin2rao/
My Stanford Home Page: https://stanford.edu/~ashlearn
CME 241 ("RL for Finance"), which I teach each Winter quarter: http://cme241.stanford.edu -
Christopher Re
Associate Professor of Computer Science
Current Research and Scholarly InterestsAlgorithms, systems, and theory for the next generation of data processing and data analytics systems.
-
Anja Redecker, MD
Postdoctoral Scholar, Chemical Engineering
BioAnja Redecker attended medical school in Germany (RWTH Aachen). For her doctoral thesis - under the guidance of Univ.-Prof. Dr. rer. nat. Lüscher – she studied the functions of a protein called ASH2L, which plays a role in tumorigenesis. She analyzed the effects of ASH2L domain deletion mutants on cell growth and histone trimethylation as well as targeted ASH2L fused to dCas9 to specific promoters and examined its effects on transcription activation.
Her current research in the Swartz Lab at Stanford University focusses on engineering Hepatitis B core virus-like particles (HBc VLP) for targeted delivery of chemotherapeutics and for vaccines. The envisioned targeting delivery system allows loading the HBc VLPs with chemotherapeutics and attaching targeting ligands like single chain antibody fragments to the HBc VLP surface. This would increase targeted accumulation of the chemotherapeutic at the tumor site and decrease therapy-limiting side effects by minimizing off-target effects. To combat any new pandemic efficiently, vaccines need to be engineered and produced quickly. This fast response can be made possible by using pre-produced HBc VLPs to which the antigen of the new circulating pathogen can be attached. This technology has the potential to curb the outbreak of a new pandemic.
